A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment.

Trial Profile

A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Buparlisib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BELLE-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 26 Oct 2017 Results of analysis assessing role of PIK3CA mutation status as a biomarker of PI3K inhibitor treatment efficacy in pts with HR+, HER2- ABC using patient data from BELLE-2 and BELLE-3 trials presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 16 Oct 2017 Planned End Date changed from 20 Sep 2017 to 8 Nov 2017.
    • 16 Oct 2017 Planned primary completion date changed from 20 Sep 2017 to 8 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top